Wells Fargo & Company Genmab A/S Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Genmab A/S stock. As of the latest transaction made, Wells Fargo & Company holds 283,111 shares of GMAB stock, worth $5.92 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

283,111

Previous 700,404 59.58%

Holding current value

$5.92 Million

Previous $17.1 Million 65.4%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$20.02 - $24.15 $8.35 Million - $10.1 Million	-417,293 Reduced 59.58%	283,111 $5.91 Million
Q3 2024 Nov 13, 2024	SELL	$23.84 - $28.48 $550,727 - $657,916	-23,101 Reduced 3.19%	700,404 $17.1 Million
Q2 2024 Aug 13, 2024	SELL	$25.13 - $30.27 $577,286 - $695,362	-22,972 Reduced 3.08%	723,505 $18.2 Million
Q1 2024 May 10, 2024	BUY	$26.43 - $32.77 $5 Million - $6.2 Million	189,345 Added 33.99%	746,477 $22.3 Million
Q4 2023 Feb 09, 2024	SELL	$27.94 - $35.44 $901,372 - $1.14 Million	-32,261 Reduced 5.47%	557,132 $17.7 Million
Q3 2023 Nov 13, 2023	SELL	$35.27 - $42.24 $1.66 Million - $1.98 Million	-46,988 Reduced 7.38%	589,393 $20.8 Million
Q2 2023 Aug 15, 2023	SELL	$37.4 - $42.94 $631,162 - $724,655	-16,876 Reduced 2.58%	636,381 $24.2 Million
Q1 2023 May 12, 2023	BUY	$34.88 - $43.22 $607,923 - $753,281	17,429 Added 2.74%	653,257 $24.7 Million
Q4 2022 Feb 13, 2023	SELL	$33.8 - $47.06 $1.21 Million - $1.68 Million	-35,718 Reduced 5.32%	635,828 $26.9 Million
Q3 2022 Nov 14, 2022	SELL	$31.52 - $373.61 $96,356 - $1.14 Million	-3,057 Reduced 0.45%	671,546 $21.6 Million
Q2 2022 Aug 12, 2022	BUY	$26.83 - $38.57 $2.05 Million - $2.95 Million	76,552 Added 12.8%	674,603 $21.9 Million
Q1 2022 May 16, 2022	BUY	$30.95 - $39.68 $2.91 Million - $3.74 Million	94,146 Added 18.68%	598,051 $21.6 Million
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $194,092 - $254,966	-5,411 Reduced 1.06%	503,905 $19.9 Million
Q3 2021 Nov 15, 2021	SELL	$41.55 - $48.72 $242,278 - $284,086	-5,831 Reduced 1.13%	509,316 $22.3 Million
Q2 2021 Aug 16, 2021	SELL	$32.88 - $44.57 $4.84 Million - $6.56 Million	-147,246 Reduced 22.23%	515,147 $21 Million
Q1 2021 May 13, 2021	SELL	$30.92 - $44.4 $2.23 Million - $3.2 Million	-72,059 Reduced 9.81%	662,393 $21.7 Million
Q4 2020 Feb 09, 2021	BUY	$33.66 - $40.76 $1.55 Million - $1.87 Million	45,953 Added 6.67%	734,452 $29.9 Million
Q3 2020 Nov 05, 2020	BUY	$33.07 - $38.68 $1.13 Million - $1.32 Million	34,088 Added 5.21%	688,499 $25.2 Million
Q2 2020 Aug 13, 2020	SELL	$20.05 - $33.89 $5.74 Million - $9.7 Million	-286,239 Reduced 30.43%	654,411 $22.2 Million
Q1 2020 May 14, 2020	BUY	$17.15 - $25.22 $16.1 Million - $23.7 Million	940,650 New	940,650 $19.9 Million

Others Institutions Holding GMAB

# of Institutions

229

Shares Held

50.9M

Call Options Held

10.2K

Put Options Held

25.5K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.8B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Genmab A/S Transaction History